Peter Hofland, PhD's Blog – May 2009 Archive (3)

Positive Data from Phase I Study of Palifosfamide in Combination with Doxorubicin offers Strongly Support for Ongoing Phase II Randomized Trial

Positive data from a Phase I study of palifosfamide (Zymafos™ or ZIO-210) in combination with doxorubicin presented at the 45th Annual American Society of Clinical Oncology (ASCO) meeting held in Orlando, FL, May 29th to June 2nd shows strong support for an ongoing Phase II Randomized Trial.

The Phase I trial of palifosfamide in combination with doxorubicin was fully enrolled… Continue

Added by Peter Hofland, PhD on May 31, 2009 at 6:30pm — No Comments

Standard of Care for Anal Cancer Should Not Be Changed

Findings from the largest trial ever conducted for anal cancer have shown that the current standard of care, using a novel, continuous radiation therapy delivery program combined with 5-fluorouracil (5-FU), a drug commonly used to treat many types of cancer including, breast, head and neck, anal, stomach, colon and some skin cancers, and mitomycin-C (a chemotherapy drug mainly used to treat bladder and rectal cancers, but also sometimes pancreatic, lung and breast cancers), results in the… Continue

Added by Peter Hofland, PhD on May 30, 2009 at 5:00pm — No Comments

Renewed Partnership with NVCI Brings Outpatient Oncology Back to UMC

Thanks to months of hard work, thoughtful planning, visionary new leadership and a generous donation from The Lincy Foundation, outpatient oncology services will once again be offered at University Medical Center (UMC). The renewed partnership between UMC and Nevada Cancer Institute (NVCI) will allow patients to receive a full complement of cancer services starting in early 2010.

Since the announcement of the closure of outpatient oncology services in late 2008, Clark… Continue

Added by Peter Hofland, PhD on May 28, 2009 at 8:00pm — No Comments